FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition/combination with antioxidant activity for treating a cerebrum disease specified in acute cerebrovascular accident (ACE), amyotrophic lateral sclerosis (ALS), transient ischemic attack (TIA) in an acute period and after a previous attack, chronic cerebral ischemia, cognitive and behavioral disorders in vascular cerebral diseases or neurodegenerative diseases. Combination with antioxidant activity for treating a cerebrum disease selected from acute cerebral circulation disorder (AMCD), amyotrophic lateral sclerosis (ALS), transient ischemic attack (TIA) in an acute period and after a previous attack, chronic cerebral ischemia, cognitive and behavioral disorders in vascular cerebral diseases or neurodegenerative diseases, wherein said combination contains effective amounts of (a) edaravon and (b) at least one substance selected from the group consisting of ebselen, resveratrol, uric acid, dehydroascorbic acid and disufen ton, and the active substances are in daily dosages: edaravon 30–700 mg/day; ebselen 200–3,600 mg / day; resveratrol 2–5,000 mg/day; uric acid 250–2,000 mg/day; dehydroascorbic acid 7,000–35,000 mg/day; sodium disufenton 500–6,000 mg/day. Pharmaceutical composition with antioxidant activity for treating a brain disease selected from AMCD, ALS, TIA in acute period and after suffered attack, chronic cerebral ischemia, cognitive and behavioral disorders in cerebral vascular diseases or neurodegenerative diseases. Kit with antioxidant activity for treating a brain disease selected from AMCD, ALS, TIA in acute period and after suffered attack, chronic cerebral ischemia, cognitive and behavioral disorders in cerebral vascular diseases or neurodegenerative diseases. Using the combination with antioxidant activity for treating a brain disease selected from AMCD, ALS, TIA in acute period and after suffered attack, chronic cerebral ischemia, cognitive and behavioral disorders in cerebral vascular diseases or neurodegenerative diseases. Use of the composition with antioxidant activity for treating a brain disease selected from AMCD, ALS, TIA in an acute period and after a previous attack, chronic cerebral ischemia, cognitive and behavioral disorders in cerebral vascular diseases or neurodegenerative diseases. Use of a kit with antioxidant activity for treating a brain disease selected from AMCD, ALS, TIA in acute period and after a previous attack, chronic cerebral ischemia, cognitive and behavioral disorders in cerebral vascular diseases or neurodegenerative diseases. Method for treating a brain disease selected from AMCD, ALS, TIA in acute period and after a previous attack, chronic cerebral ischemia, cognitive and behavioral disorders in cerebral vascular diseases or neurodegenerative diseases, in which the neuroprotective preparations are used in effective amounts of a combination, composition or kit.
EFFECT: above described combination or kit or composition have a synergetic antioxidant effect, are effective for treating a brain disease selected from AMCD, ALS, TIA in acute period and after suffered attack, chronic cerebral ischemia, cognitive and behavioral disorders in cerebral vascular diseases or neurodegenerative diseases.
24 cl, 16 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
BIOACTIVE COMPOSITION BASED ON A CROSSLINKED HYALURONIC ACID SALT CONTAINING RESVERATROL AND A METHOD OF ITS PREPARATION | 2020 |
|
RU2745124C1 |
MEDICINAL AGENT FOR PREVENTING AND TREATING CEREBRAL DISEASES AND METHOD OF TREATING CEREBRAL DISEASES | 2015 |
|
RU2692063C2 |
COMBINATION FOR TREATING AND PREVENTING BEHAVIOURAL, MENTAL, COGNITIVE AND NEUROLOGICAL DISORDERS ACCOMPANYING ORGANIC CNS DISEASES | 2012 |
|
RU2493838C1 |
DPP-IV INHIBITORS FOR TREATMENT OF NEURODEGENERATION AND COGNITIVE DISORDERS | 2005 |
|
RU2394570C2 |
COMBINATIONS OF COMPOUNDS MODULATING THE NMDA RECEPTOR | 2015 |
|
RU2721948C2 |
TREATMENT METHOD INCLUDING ORAL OR GASTRIC EXCRETION OF EDARAVON | 2018 |
|
RU2761967C2 |
SUBLINGUAL PHARMACEUTICAL COMPOSITION OF EDARAVONE AND (+)-2-BORNEOL | 2017 |
|
RU2720204C1 |
LIGAND WITH WIDE RANGE OF SIMULTANEOUS RECEPTOR ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD OF PREPARING SAID COMPOSITION AND MEDICINAL AGENT | 2008 |
|
RU2374245C1 |
ESTROGEN COMPONENTS FOR APPLICATION IN NEUROLOGICAL DISORDERS TREATMENT | 2013 |
|
RU2627846C2 |
TREATMENT METHOD FOR AMYOTROPHIC LATERAL SCLEROSIS | 2023 |
|
RU2804196C1 |
Authors
Dates
2019-07-03—Published
2017-11-03—Filed